

# CITATION REPORT

List of articles citing

## Sotrovimab: First Approval.

DOI: 10.1007/s40265-022-01690-7  
Drugs, 2022, 82, 477-484.

**Source:** <https://exaly.com/paper-pdf/134863590/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis.. <i>Journal of Infection</i> , <b>2022</b> ,	18.9	1
20	COVID-19-Current Therapeutical Approaches and Future Perspectives. <i>Processes</i> , <b>2022</b> , 10, 1053	2.9	1
19	Antibodies against SARS-CoV-2 after natural infection in healthcare workers and clinical characteristics as putative antibody production prediction. <i>Journal of Clinical Virology Plus</i> , <b>2022</b> , 100089		
18	Decoding the Effects of Spike Receptor Binding Domain Mutations on Antibody Escape Abilities of Omicron Variants.		
17	Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. <b>2022</b> , 23, 9297		1
16	Etiotropic therapy of the new coronavirus infection. Expectations and realities. Part 2. <b>2022</b> , 26, 7-12		0
15	Decoding the effects of spike receptor binding domain mutations on antibody escape abilities of omicron variants. <b>2022</b> , 627, 168-175		0
14	Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections. 9,		0
13	Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.		0
12	Nitric oxide and its derivatives containing nasal spray and inhalation therapy for the treatment of COVID-19. <b>2022</b> , 29,		0
11	A Review of Potential Therapeutic Strategies for COVID-19. <b>2022</b> , 14, 2346		1
10	Humoral response after a third and fourth dose of mRNA-based SARS-CoV-2 vaccine in previously seronegative kidney transplant recipients.		0
9	Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. <b>2022</b> , 77, 102172		0
8	An Overview of Repurposed Drugs for Potential COVID-19 Treatment. <b>2022</b> , 11, 1678		0
7	Development of therapeutic antibodies for the treatment of diseases. <b>2022</b> , 3,		1
6	Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis. 1-22		1
5	Therapeutic developments for SARS-CoV-2 infection Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice. 14,		0

- 4 Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience. 1-7 ○
- 3 In silico evaluation of anti SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab. ○
- 2 Sotrovimab restores neutralisation against current Omicron subvariants in patients with blood cancer. **2023**, ○
- 1 Severe COVID-19: Drugs and Clinical Trials. **2023**, 12, 2893 ○